- Investors don't seem impressed with top-line data from two Phase 3 trials of Tesaro's (TSRO) NK-1 receptor antagonist rolapitant in chemotherapy-induced nausea and vomiting.
- The studies met their primary endpoints of CR (no vomiting and no use of rescue medication) in the delayed phase.
- However, neither trial hit statistical significance in the acute and overall phases (secondary endpoints).
- The company says preparations are ongoing for an NDA submission in mid-2014. (PR)
- TSRO -14% premarket.